Michael F T Koehler

This inventor holds 12 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Genentech, Inc., Curis, Inc., Rqx Pharmaceuticals, Inc.. Active years: 2011-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael F T Koehler. Retrieved from https://idiyas.com/inventor/michael-f-t-koehler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 6)

% Patents Active = 66.7

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 70(Granted Patents)

Location History:

Burlingame, CA (US) (2012)
Palo Alto, CA (US) (2011 - 2021)
South San Francisco, CA (US) (2021)

Company Filing History:

Rqx Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2011-2021

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11208387 - Macrocyclic broad spectrum antibiotics (2021-12-28),

2. 11072635 - Macrocyclic broad spectrum antibiotics (2021-07-27),

3. 10392422 - Macrocyclic broad spectrum antibiotics (2019-08-27),

4. 9790183 - Pyridyl inhibitors of hedgehog signalling (2017-10-17),

5. 9321761 - Pyridyl inhibitors of hedgehog signalling (2016-04-26),

6. 9278961 - Pyridyl inhibitors of hedgehog signalling (2016-03-08),

7. 8907092 - Inhibitors of IAP (2014-12-09),

8. 8273743 - Quinoxaline inhibitors of the hedgehog signalling (2012-09-25),

9. 8247557 - IAP inhibitors (2012-08-21),

10. 8168645 - Arylsulfonamide compounds (2012-05-01),

11. 8163763 - Pyrimidine compounds, compositions and methods of use (2012-04-24),

12. 8063218 - Imidazopyridine inhibitors of IAP (2011-11-22),

Title: Michael F T Koehler: Innovator in Antibiotic Development

Introduction

Michael F T Koehler is a prominent inventor based in Palo Alto, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibacterial compounds. With a total of 12 patents to his name, Koehler's work has had a substantial impact on antibiotic research and treatment methodologies.

Latest Patents

Koehler's latest patents focus on macrocyclic broad spectrum antibiotics. These patents describe antibacterial compounds that exhibit broad spectrum bioactivity. In various embodiments, the compounds act by inhibiting bacterial type 1 signal peptidases SpsB and/or LepB, which are essential proteins in bacteria. Additionally, the patents provide pharmaceutical compositions and methods for treatment using these innovative compounds.

Career Highlights

Throughout his career, Koehler has worked with notable companies such as Genentech, Inc. and Curis, Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in antibiotic development.

Collaborations

Some of Koehler's coworkers include Daniel P Sutherlin and Cuong Q Ly. Their collaborative efforts have further advanced the research and development of new antibacterial therapies.

Conclusion

Michael F T Koehler's contributions to antibiotic research and his innovative patents highlight his role as a key figure in the pharmaceutical industry. His work continues to influence the development of effective treatments for bacterial infections.

Profile summary based on public USPTO records.